To overcome the limitation of EpCAM‐mediated CTC enrichment and to capture CTCs irrespective of their EMT status, antibody cocktails against EGFR and HER2 (tumor‐specific markers), CDH11 (a cadherin specifically overexpressed in mesenchymal tumor cells), as well as cell surface vimentin (expressed in cancer cells of mesenchymal lineage) (Armstrong et al., 2011; Satelli et al., 2015a; Yu et al., 2013), have been used in combination with EpCAM antibodies. Here, EPCAM is linked to cancer.